The aim of this protocol is to determine whether long-term administration of recombinant human insulin-like growth factor I (rhIGF-I), at doses ranging from 80 ug/kg given BID, by subcutaneous injection to children with GHIS continues to be safe and effective and can restore normal growth to children with GHIS.
Showing the most recent 10 out of 782 publications